14.3 Weight Reduction and Long-term Maintenance Study of WEGOVY Injection in Pediatric Patients Aged 12 Years and Older with Obesity SPL UNCLASSIFIED SECTION Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to 95th percentile standardized for age and sex (Study 10) (NCT#04102189)
Where periostin comes from in the bodyIt is produced mainly by mesenchymal-lineage cells such as osteoblasts, fibroblasts, and cells in the periosteum, tendons, periodontal ligament, and cardiac valves
More research is needed to confirm the efficacy and safety of Ozempic as an anti-addiction drug and it could be years before it could be FDA approved for addiction treatment
Its sometimes referred to online as a wolverine peptide because much of the interest centers on tissue repair
Co-agonist strategy Glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptor (GCGR) are currently the primary targets alongside GLP-1R for combined stimulation